Company press releases
Released | Company | Title | Industry | Topic |
---|---|---|---|---|
17 Oct 2024 08:50 CEST |
BenevolentAI | BenevolentAI Appoints Kenneth Mulvany as Executive Chairman | 20103010 Biotechnology | Other subject |
19 Sep 2024 07:00 CEST |
BenevolentAI | BenevolentAI Interim Results for the Six Months Ended 30 June 2024 | 20103010 Biotechnology | Commercial operations |
03 Jul 2024 07:00 CEST |
BenevolentAI | BenevolentAI: Leadership Team Change | 20103010 Biotechnology | Other subject |
02 May 2024 15:30 CEST |
BenevolentAI | BenevolentAI: Result of Annual General Meeting | 20103010 Biotechnology | General meeting / Board Meeting |
23 Apr 2024 07:00 CEST |
BenevolentAI | BenevolentAI Provides an Update on Its Business Priorities | 20103010 Biotechnology | Commercial operations |
17 Apr 2024 07:00 CEST |
BenevolentAI | BenevolentAI: Publication of the Revised Agenda for the 2024 AGM | 20103010 Biotechnology | General meeting / Board Meeting |
15 Apr 2024 07:00 CEST |
BenevolentAI | Proposed Changes to BenevolentAI’s Board Composition | 20103010 Biotechnology | Journal / appointments |
25 Mar 2024 07:00 CET |
BenevolentAI | BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers | 20103010 Biotechnology | Commercial operations |
20 Mar 2024 07:00 CET |
BenevolentAI | BenevolentAI: Publication of 2023 Annual Report and 2024 AGM Notice | 20103010 Biotechnology | General meeting / Board Meeting |
14 Mar 2024 07:00 CET |
BenevolentAI | BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023 | 20103010 Biotechnology | Commercial operations |
24 Jan 2024 07:00 CET |
BenevolentAI | BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer | 20103010 Biotechnology | Journal / appointments |
28 Dec 2023 07:00 CET |
BenevolentAI | BenevolentAI:Shareholder Letter December 2023 | 20103010 Biotechnology | Other subject |
21 Sep 2023 07:01 CEST |
BenevolentAI | BenevolentAI: Interim Results for the Six Months Ended 30 June 2023 | 20103010 Biotechnology | Other subject |
21 Sep 2023 07:00 CEST |
BenevolentAI | BenevolentAI: Directorate Change | 20103010 Biotechnology | Journal / appointments |
20 Sep 2023 07:00 CEST |
BenevolentAI | BenevolentAI Signs Strategic Collaboration with Merck | 20103010 Biotechnology | Other subject |
18 Sep 2023 07:00 CEST |
BenevolentAI | BenevolentAI Welcomes Christina Busmalis as its New Chief Revenue Officer | 20103010 Biotechnology | Journal / appointments |
15 Sep 2023 07:00 CEST |
BenevolentAI | BenevolentAI Notice of Interim Results | 20103010 Biotechnology | Other subject |
11 Sep 2023 07:00 CEST |
BenevolentAI | BenevolentAI: Appointment of Catherine Isted, ACMA, as Chief Financial Officer | 20103010 Biotechnology | Journal / appointments |
31 Aug 2023 07:00 CEST |
BenevolentAI | BenevolentAI Doses First Participants in Clinical Trial of BEN-8744; Targets PDE10, an AI-derived Novel Target for the Treatment of Ulcerative Colitis | 20103010 Biotechnology | New |
21 Jun 2023 07:00 CEST |
BenevolentAI | BenevolentAI: Board Change | 20103010 Biotechnology | Journal / appointments |
25 May 2023 07:00 CEST |
BenevolentAI | BenevolentAI Unveils Strategic Plan to Position the Company for a New Era in AI | 20103010 Biotechnology | Other subject |
05 Apr 2023 07:00 CEST |
BenevolentAI | BenevolentAI Announces Top-Line Phase IIa Results for Its Topical pan-Trk Inhibitor BEN-2293 (1%) in Mild-to-Moderate Atopic Dermatitis | 20103010 Biotechnology | New |
24 Mar 2023 07:00 CET |
BenevolentAI | BenevolentAI Announces Publication of Convening Notice for AGM | 20103010 Biotechnology | General meeting / Board Meeting |
22 Mar 2023 07:00 CET |
BenevolentAI | BenevolentAI Strengthens its Board of Directors with the Appointment of Digital Innovation Expert Marcello Damiani | 20103010 Biotechnology | New |
16 Mar 2023 07:00 CET |
BenevolentAI | BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022 | 20103010 Biotechnology | Income |
06 Oct 2022 07:00 CEST |
BenevolentAI | BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca | 20103010 Biotechnology | New |
27 Sep 2022 14:55 CEST |
BenevolentAI | BenevolentAI Analyst / Investor Event | 20103010 Biotechnology | Meetings / events |
27 Sep 2022 07:00 CEST |
BenevolentAI | BenevolentAI Interim Results for the Six Months Ended 30 June 2022 | 20103010 Biotechnology | Income |